Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study

Background: Patients with refractory mCRC rarely undergo third-line or subsequent treatment. This strategy could negatively impact their survival. In this setting, regorafenib (R) and trifluridine/tipiracil (T) are two key new treatment options with statistically significant improvements in overall...

Полное описание

Библиографические подробности

Главные авторы:	Carlo Signorelli, Maria Alessandra Calegari, Michele Basso, Annunziato Anghelone, Jessica Lucchetti, Alessandro Minelli, Lorenzo Angotti, Ina Valeria Zurlo, Marta Schirripa, Mario Giovanni Chilelli, Cristina Morelli, Emanuela Dell’Aquila, Antonella Cosimati, Donatello Gemma, Marta Ribelli, Alessandra Emiliani, Domenico Cristiano Corsi, Giulia Arrivi, Federica Mazzuca, Federica Zoratto, Maria Grazia Morandi, Fiorenza Santamaria, Rosa Saltarelli, Enzo Maria Ruggeri
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2023-06-01
Серии:	Current Oncology
Предметы:	metastatic colorectal cancer regorafenib trifluridine/tipiracil third-line therapy real-world study
Online-ссылка:	https://www.mdpi.com/1718-7729/30/6/413
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!